Last reviewed · How we verify
Bromfenac Sodium 0.07%
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.
Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye. Used for Postoperative inflammation and pain following cataract surgery, Ocular itching associated with allergic conjunctivitis.
At a glance
| Generic name | Bromfenac Sodium 0.07% |
|---|---|
| Sponsor | Retina Research Institute, LLC |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase (COX-1 and COX-2) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bromfenac sodium ophthalmic solution works by blocking COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and swelling. By reducing prostaglandin levels in ocular tissues, it decreases postoperative inflammation and pain following cataract surgery and other ocular procedures. The 0.07% formulation is a topical ophthalmic preparation applied directly to the eye surface.
Approved indications
- Postoperative inflammation and pain following cataract surgery
- Ocular itching associated with allergic conjunctivitis
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Headache
- Foreign body sensation
Key clinical trials
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen (PHASE4)
- NSAID vs Steroid in Trabeculectomy Wound Management (PHASE4)
- Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial (PHASE4)
- Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (NA)
- Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bromfenac Sodium 0.07% CI brief — competitive landscape report
- Bromfenac Sodium 0.07% updates RSS · CI watch RSS
- Retina Research Institute, LLC portfolio CI